Facebook
Twitter
Telegram
Report an ErrorLandos Biopharma Balance Sheet 2011-2024 | LABP
Annual Balance Sheet Landos Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -2.42 M | -9.81 M | -359 K | - | - | - | - | - | - | - |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 73 M | - | - | - | - | - | - | - | - |
Total Current Liabilities |
6.25 M | 6.12 M | 16.6 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
6.25 M | 6.12 M | 16.6 M | 11.3 M | 76.1 M | 1.8 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-155 M | -133 M | -94.2 M | - | -25.6 M | -9.14 M | - | - | - | - | - | - | - |
Total Assets |
38 M | 45.3 M | 92.9 M | 30.3 M | 50.5 M | 2.8 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
37.5 M | 36.6 M | 8.3 M | 2.42 M | - | - | - | - | - | - | - | - | - |
Book Value |
31.8 M | 39.1 M | 76.3 M | 19 M | -25.6 M | 1 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
31.8 M | 39.1 M | 76.3 M | -54 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Landos Biopharma
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
5.57 M | 3.02 M | 4.16 M | 6.12 M | 5.48 M | 6.51 M | 15.5 M | 16.6 M | 11.2 M | 12.7 M | 9.03 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-149 M | -143 M | -139 M | -133 M | -128 M | -120 M | -109 M | -94.2 M | -74.1 M | -61.4 M | -65.5 M | -55.7 M | -55.7 M | -55.7 M | -55.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
43.2 M | 46.3 M | 51.2 M | 45.3 M | 49.5 M | 58 M | 77.6 M | 92.9 M | 105 M | 118 M | 110 M | 30.3 M | 30.3 M | 30.3 M | 30.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
42.4 M | 44 M | 45.2 M | 36.6 M | 28.9 M | 19.2 M | 11.3 M | 8.3 M | 17.9 M | 18.7 M | 8.57 M | 2.42 M | 2.42 M | 2.42 M | 2.42 M | 9.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
37.7 M | 43.3 M | 47 M | 39.1 M | 44 M | 51.5 M | 62.1 M | 76.3 M | 93.9 M | 106 M | 101 M | 19 M | 19 M | 19 M | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
37.7 M | 43.3 M | 47 M | 39.1 M | 44 M | 51.5 M | 62.1 M | 76.3 M | 93.9 M | 106 M | 101 M | -54 M | -54 M | -54 M | -54 M | -25.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency